Allergy experts weigh ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape atopic dermatitis care beyond steroids.
Back
Reassessing Topical Approaches in Atopic Dermatitis: Risks, Benefits, and New Options in 2026
A trio of clinical forums spotlighting evolving trends in atopic dermatitis, including how advanced understanding and therapeutic options change discussions around management in 2026.
Reassessing Topical Approaches in Atopic Dermatitis: Risks, Benefits, and New Options in 2026
Episodes
All
All
Experts unpack where new eczema creams fit, and why insurance hurdles and steroid fear keep patients from faster itch relief.
Advertisement
Advertisement
Trending on HCPLive
1
Combination Therapy, Adherence, and Access: A PAH Expert Roundtable
2
Allergists Debate Newer Nonsteroidal Topicals for Atopic Dermatitis
3
CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation
4
Ritlecitinib Improves Repigmentation in Nonsegmental Vitiligo Phase 3 Data
5